Overview
GRAL market data
Price History
GRAL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$11.11 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.84 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -253.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $29.95 – $118.84 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.3B · P/B 1.29 · P/S 21.41.
Company News
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection TestBenzinga · Aug 10, 2026, 5:30 PM
GRAIL's Galleri Multi-Cancer Blood Test PMA Set For FDA Advisory Committee Review On Sept. 23Benzinga · Aug 7, 2026, 3:12 PM
GRAIL Q2 EPS $(2.56) Beats $(2.62) Estimate, Sales $44.687M Beat $42.760M EstimateBenzinga · Aug 5, 2026, 8:14 PM
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff RolGlobenewswire Inc · Jul 29, 2026, 10:30 PM
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff RoleGlobenewswire Inc · Jul 20, 2026, 11:00 PM
GRAIL Collaborates With Priority Health To Make GRAIL's Galleri Multi-Cancer Early Detection Test Available To Priority Health's Self-Insured Employer GroupsBenzinga · Jul 16, 2026, 1:06 PM
Mizuho Maintains Neutral on GRAIL, Raises Price Target to $65Benzinga · Jul 15, 2026, 6:27 PM
Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.The Motley Fool · Jul 13, 2026, 12:45 PM
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout – HBSSGlobenewswire Inc · Jul 8, 2026, 7:15 PM
GRAL Investors Have Rights – If You Lost Money Investing in Grail, Inc. Contact Robbins LLP for Information About Recovering Your LossesGlobenewswire Inc · Jul 1, 2026, 11:15 PM